Considerations for Novel COVID-19 Mucosal Vaccine Development
Mucosal surfaces are the first contact sites of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most SARS-CoV-2 vaccines induce specific IgG responses but provide limited mucosal immunity. Cytokine B-cell activation factor (BAFF) and A proliferation-inducing ligand (APRIL) in the t...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI AG
2022-07-01
|
| Reeks: | Vaccines |
| Onderwerpen: | |
| Online toegang: | https://www.mdpi.com/2076-393X/10/8/1173 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|